Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Nanfang Hospital, Southern Medical University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06177925CT.gov A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | — | Recruiting | — | — | — |
NCT05241873CT.gov (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | — | Terminated | — | — | — |
NCT05153408CT.gov (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | — | Terminated | — | — | — |
NCT03134872CT.gov A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bronchial Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | Nanfang Hospital, Southern Medical University | P3 | BB · 68 |
| Vinorelbine Ditartrate | University of Turin, Italy | P3 | B |
| Docetaxel | University of Turin, Italy | P3 | B |
| Icotinib | Sun Yat-sen University | P2 | B |
| Adebrelimab | Nanfang Hospital, Southern Medical University | P2 | CCC |
| Cis-Diamminedichloroplatinum Ii | Nanfang Hospital, Southern Medical University | P2 | CCC |
| Etoposide | Nanfang Hospital, Southern Medical University | P2 | CCC |
| Alectinib | Hoffmann-La Roche | P2 | CCC |
| Nivolumab | University of Colorado, Denver | P2 | CCC |
+9 more in the Bronchial Neoplasm cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Carboplatin in Bronchial Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-bronchial-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →